RANI

SEC source: 0000899243-22-019858 · doc4.xml · derivative · entry 1

Nanavaty Maulik · CIK 0001529708 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,416

Underlying: Class A Common Stock · 41,416 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019854 · doc4.xml · derivative · entry 1

Baranowski Lyn · CIK 0001893640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,240

Underlying: Class A Common Stock · 22,240 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0000899243-22-019856 · doc4.xml · derivative · entry 1

Rometty Lisa Ann · CIK 0001902958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,112

Underlying: Class A Common Stock · 16,112 shares

Expires 2032-05-24

F1 · derivative.exercise_date: The shares subject to the option vest in full on the first anniversary of the date of grant, subject to the recipient's Continuous Service (as defined in the Company's 2021 Equity Incentive Plan) through such vesting date; provided, that, if earlier, the shares subject to the option will vest in full upon the occurrence of either of the following events: the Company's next annual stockholder meeting or a Change in Control (as defined in the 2021 Equity Incentive Plan).

SEC source: 0001209191-22-021018 · doc4.xml · derivative · entry 2

Hashim Mir · CIK 0001875891 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,400

Underlying: Class A Common Stock · 125,400 shares

Expires 2032-03-21

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.

SEC source: 0001209191-22-021018 · doc4.xml · nonDerivative · entry 1

Hashim Mir · CIK 0001875891 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 158,800

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022.

SEC source: 0001209191-22-021022 · doc4.xml · derivative · entry 2

Imran Talat · CIK 0001869579 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 263,400

Underlying: Class A Common Stock · 263,400 shares

Expires 2032-03-21

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.

SEC source: 0001209191-22-021022 · doc4.xml · nonDerivative · entry 1

Imran Talat · CIK 0001869579 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,943

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022.

SEC source: 0001209191-22-021021 · doc4.xml · derivative · entry 2

Sanford Svai S · CIK 0001591411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Class A Common Stock · 100,000 shares

Expires 2032-03-21

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.

SEC source: 0001209191-22-021021 · doc4.xml · nonDerivative · entry 1

Sanford Svai S · CIK 0001591411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,100

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022.

SEC source: 0001209191-22-021014 · doc4.xml · derivative · entry 2

Groen Eric · CIK 0001918630 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,400

Underlying: Class A Common Stock · 74,400 shares

Expires 2032-03-21

F2 · derivative.exercise_date: The shares subject to the option vest as follows: 1/48th of the shares subject to the option vest monthly over four years from March 22, 2022.

SEC source: 0001209191-22-021014 · doc4.xml · nonDerivative · entry 1

Groen Eric · CIK 0001918630 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,500

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 25% of the RSUs shall vest yearly over four years from March 22, 2022.

SEC source: 0001179110-22-002126 · edgar.xml · derivative · entry 4

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 22,667,747

Underlying: Class A Common Stock · 2,309,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002126 · edgar.xml · nonDerivative · entry 3

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 147,959

F2 · kind: InCube Ventures II, L.P. distributed these shares to its limited partners on a pro rata basis, for no consideration

F5 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002126 · edgar.xml · nonDerivative · entry 2

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 2,377,197

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F4 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002126 · edgar.xml · nonDerivative · entry 1

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 22,667,747

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F3 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002127 · edgar.xml · derivative · entry 4

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 256,623

Underlying: Class A Common Stock · 2,309,490 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F1 · derivative.exercise_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F1 · derivative.expiration_date: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F6 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 LLC Units previously held by InCube Ventures II, L.P. and 80,252 LLC Units previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 3

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 146,379

F2 · kind: InCube Ventures II, L.P. distributed these shares to its limited partners on a pro rata basis, for no consideration

F5 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F5 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. Represents 2,229,238 Class A Shares previously held by InCube Ventures II, L.P. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 2

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 2,375,617

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F4 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class A Shares held by InCube Ventures II, L.P. and 80,252 Class A Shares held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001179110-22-002127 · edgar.xml · nonDerivative · entry 1

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote.

Disclosed balance after: 256,623

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: Pursuant to the terms of the Fifth Amended and Restated LLC Agreement between Rani Therapeutics, LLC, a direct subsidiary of the Issuer, and the holders of its Common LLC Units ("LLC Units"), InCube Ventures II, L.P. and Rani Investment Corp. elected to exchange on a one-for-one basis the LLC Units and redeem the corresponding number of shares of Class B Common Stock of the Issuer ("Class B Shares") for newly-issued shares of Class A Common Stock of the Issuer ("Class A Shares").

F3 · shares: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: The Reporting Person is a General Partner of InCube Ventures II, L.P. and Rani Investment Corp. Represents 2,229,238 Class B Shares previously held by InCube Ventures II, L.P. and 80,252 Class B Shares previously held by Rani Investment Corp. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-007642 · doc4.xml · nonDerivative · entry 2

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 67,707

F3 · shares: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · shares: InCube Labs, L.L.C., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Labs, L.L.C. therefore received 3,181 Class A Shares distributed by Biologix Partners, LP and 10,742 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · ownership.nature: InCube Labs, L.L.C., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Labs, L.L.C. therefore received 3,181 Class A Shares distributed by Biologix Partners, LP and 10,742 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-007642 · doc4.xml · nonDerivative · entry 1

IMRAN MIR A · CIK 0001031686 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.

F2 · shares: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP.

F2 · ownership.nature: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP.

SEC source: 0001209191-22-007647 · doc4.xml · nonDerivative · entry 2

Imran Talat · CIK 0001869579 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 12,343

F3 · shares: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person is a member of the general partner and disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-007647 · doc4.xml · nonDerivative · entry 1

Imran Talat · CIK 0001869579 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.

F2 · shares: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F2 · ownership.nature: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-007637 · doc4.xml · nonDerivative · entry 2

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 66,127

F3 · shares: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · shares: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F3 · ownership.nature: InCube Ventures II, L.P., is the limited partner of Biologix Partners, LP and VH Rani, LP. InCube Ventures II, L.P. therefore received 12,289 Class A Shares distributed by Biologix Partners, LP and 41,495 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

F4 · ownership.nature: VH Moll, L.P., is a limited partner of VH Rani, LP. VH Moll, L.P. therefore received 12,343 Class A Shares distributed by VH Rani, LP. and now owns those shares directly. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

SEC source: 0001209191-22-007637 · doc4.xml · nonDerivative · entry 1

Farquharson Andrew · CIK 0001865699 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: Biologix Partners, LP and VH Rani, LP. distributed these shares to its limited partners on a pro rata basis, for no consideration.

F2 · shares: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP.

F2 · ownership.nature: Represents previously held 378,564 shares of Class A Common Stock of the Issuer ("Class A Shares") held by Biologix Partners, LP and 448,903 Class A Shares held by VH Rani, LP.

SEC source: 0001209191-22-007638 · doc4.xml · nonDerivative · entry 1

Nanavaty Maulik · CIK 0001529708 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By spouse

Disclosed balance after: 11,017

F1 · kind: Received in kind pro rata distribution from VH Rani, LP. to its limited partners.

SEC source: 0001209191-22-007636 · doc4.xml · nonDerivative · entry 1

InCube Labs, L.L.C. · CIK 0001873082 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,923

F1 · kind: Received in kind pro rata distribution from Biologix Partners, LP (3,181 shares of Class A Common Stock) and VH Rani, LP. (10,742 shares of Class A Common Stock), to its limited partners.

SEC source: 0001209191-22-001967 · doc4.xml · derivative · entry 1

Rometty Lisa Ann · CIK 0001902958 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,037

Underlying: Class A Common Stock · 49,037 shares

Expires 2032-01-03

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on January 3, 2023; and 1/36th of the shares subject to the option vest monthly thereafter over the following two years.

SEC source: 0001209191-21-064339 · doc4.xml · derivative · entry 1

Baranowski Lyn · CIK 0001893640 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,695

Underlying: Class A Common Stock · 31,695 shares

Expires 2031-11-09

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 1/3rd of the shares subject to the option vest on November 10, 2022; and 1/36th of the shares subject to the option vest monthly thereafter over the following two years.

SEC source: 0001209191-21-055764 · doc4.xml · nonDerivative · entry 1

Hashim Mir · CIK 0001875891 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 117,600

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 50% of the RSUs shall vest on September 9, 2022, and 50% shall vest on September 9, 2023.

SEC source: 0001209191-21-055770 · doc4.xml · derivative · entry 1

Imran Talat · CIK 0001869579 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 725,000

Underlying: Class A Common Stock · 725,000 shares

Expires 2031-09-09

F1 · derivative.exercise_date: The shares subject to the option vest as follows: 25% of the shares subject to the option vests on June 14, 2022; and 1/48th of the shares subject to the option vest monthly thereafter over the following three years.

SEC source: 0001209191-21-055777 · doc4.xml · nonDerivative · entry 1

Sanford Svai S · CIK 0001591411 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,200

F1 · deemedExecutionDate: The shares subject to the restricted stock unit grant vest as follows: 50% of the RSUs shall vest on September 9, 2022, and 50% shall vest on September 9, 2023.

SEC source: 0001104659-21-099595 · tm2124024-2_4seq1.xml · nonDerivative · entry 3

Quiroga Moreno Isidoro · CIK 0001794307 · 10% owner

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through South Lake One LLC

Disclosed balance after: 11,731,654

F3 · kind: In connection with the Issuer's initial public offering, South Lake One LLC ("South Lake") acquired, at a price of $11.00 per share of Class A Common Stock, 3,572,727 shares of the Issuer's Class A Common Stock for an aggregate purchase price of $39,299,997.

F5 · ownership.nature: Isidoro Quiroga Moreno indirectly controls South Lake, which has sole voting power and sole dispositive power with respect to all of the shares of the Issuer's Class A Common Stock held by it. South Lake is wholly owned by South Cone, which is controlled by its general partner El Aromo, which is controlled by Isidoro Quiroga Moreno (who directly owns approximately 71% of the issued and outstanding capital stock of El Aromo).

SEC source: 0001104659-21-099595 · tm2124024-2_4seq1.xml · nonDerivative · entry 2

Quiroga Moreno Isidoro · CIK 0001794307 · 10% owner

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 8,158,927

F2 · kind: In connection with the Issuer's initial public offering, Aequanimitas acquired, at a price of $11.00 per share of Class A Common Stock, 2,727,273 shares of the Issuer's Class A Common Stock for an aggregate purchase price of $30,000,003.

F4 · ownership.nature: Isidoro Quiroga Moreno indirectly controls Aequanimitas, which has sole voting power and sole dispositive power with respect to all of the shares of the Issuer's Class A Common Stock held by it. Aequanimitas is controlled by its general partner, South Lake Three LLC, which is wholly owned by South Cone Investments Limited Partnership ("South Cone"), which is controlled by its general partner Inversiones El Aromo Limitada ("El Aromo"), which is controlled by Isidoro Quiroga Moreno (who directly owns approximately 71% of the issued and outstanding capital stock of El Aromo).

SEC source: 0001104659-21-099595 · tm2124024-2_4seq1.xml · nonDerivative · entry 1

Quiroga Moreno Isidoro · CIK 0001794307 · 10% owner

South Cone Investments Limited Partnership · CIK 0001876412 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · Shares indirectly held through Aequanimitas Limited Partnership

Disclosed balance after: 5,431,654

F1 · kind: Aequanimitas Limited Partnership ("Aequanimitas") acquired 158,904 shares of the Issuer's Class A Common Stock in a single transaction in the open market at a price of $11.2525 per share of Class A Common Stock for an aggregate purchase price of $1,788,067.26.

F4 · ownership.nature: Isidoro Quiroga Moreno indirectly controls Aequanimitas, which has sole voting power and sole dispositive power with respect to all of the shares of the Issuer's Class A Common Stock held by it. Aequanimitas is controlled by its general partner, South Lake Three LLC, which is wholly owned by South Cone Investments Limited Partnership ("South Cone"), which is controlled by its general partner Inversiones El Aromo Limitada ("El Aromo"), which is controlled by Isidoro Quiroga Moreno (who directly owns approximately 71% of the issued and outstanding capital stock of El Aromo).